| DOI | Resolve DOI: https://doi.org/10.1093/stmcls/sxad059 |
|---|
| Author | Search for: Alasmar, Salma1; Search for: Huang, Jez; Search for: Chopra, Karishma; Search for: Baumann, Ewa1; Search for: Aylsworth, Amy1; Search for: Hewitt, Melissa1; Search for: Sandhu, Jagdeep K.1; Search for: Tauskela, Joseph S.1; Search for: Ben, Robert N.; Search for: Jezierski, Anna1ORCID identifier: https://orcid.org/0000-0002-0837-4678 |
|---|
| Affiliation | - National Research Council of Canada. Human Health Therapeutics
|
|---|
| Funder | Search for: Canadian Institutes of Health Research |
|---|
| Format | Text, Article |
|---|
| Abstract | Human induced pluripotent stem cells (iPSCs) and iPSC-derived neurons (iPSC-Ns) represent a differentiated modality toward developing novel cell-based therapies for regenerative medicine. However, the successful application of iPSC-Ns in cell-replacement therapies relies on effective cryopreservation. In this study, we investigated the role of ice recrystallization inhibitors (IRIs) as novel cryoprotectants for iPSCs and terminally differentiated iPSC-Ns. We found that one class of IRIs, N-aryl-D-aldonamides (specifically 2FA), increased iPSC post-thaw viability and recovery with no adverse effect on iPSC pluripotency. While 2FA supplementation did not significantly improve iPSC-N cell post-thaw viability, we observed that 2FA cryopreserved iPSC-Ns re-established robust neuronal network activity and synaptic function much earlier compared to CS10 cryopreserved controls. The 2FA cryopreserved iPSC-Ns retained expression of key neuronal specific and terminally differentiated markers and displayed functional electrophysiological and neuropharmacological responses following treatment with neuroactive agonists and antagonists. We demonstrate how optimizing cryopreservation media formulations with IRIs represents a promising strategy to improve functional cryopreservation of iPSCs and post-mitotic iPSC-Ns, the latter of which have been challenging to achieve. Developing IRI enabling technologies to support an effective cryopreservation and an efficiently managed cryo-chain is fundamental to support the delivery of successful iPSC-derived therapies to the clinic. |
|---|
| Publication date | 2023-08-25 |
|---|
| Publisher | Oxford Academic |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | c5e144ac-9c60-4816-b5aa-c21714ff4091 |
|---|
| Record created | 2024-07-26 |
|---|
| Record modified | 2024-07-26 |
|---|
